: Fluoropyrimidine, platinum, and irinotecan (eg, FOLFIRINOX [5-FU/leucovorin/oxaliplatin/irinotecan]) Regimens with gemcitabine and nab-paclitaxel Gemcitabine monotherapy Other regimens Predictor Preselection Predictors were selected based on
Search Results
SOURCE-PANC: A Prediction Model for Patients With Metastatic Pancreatic Ductal Adenocarcinoma Based on Nationwide Population-Based Data
Héctor G. van den Boorn, Willemieke P.M. Dijksterhuis, Lydia G.M. van der Geest, Judith de Vos-Geelen, Marc G. Besselink, Johanna W. Wilmink, Martijn G.H. van Oijen, and Hanneke W.M. van Laarhoven
Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature
Medhavi Gupta, Christopher Sherrow, Maghan E. Krone, Edik M. Blais, Michael J. Pishvaian, Emanuel F. Petricoin III, Lynn M. Matrisian, Patricia DeArbeloa, Gary Gregory, Alyson Brown, Olivia Zalewski, Gillian Prinzing, Charles Roche, Kazunori Kanehira, Sarbajit Mukherjee, Renuka Iyer, and Christos Fountzilas
surveillance CT 6 months later showed disease progression with enlarging lymph nodes. Gemcitabine was reintroduced at a lower dose of 800 mg/m 2 on days 1 and 8 of a 21-day cycle. Nab-paclitaxel was added to gemcitabine from cycle 6 onward because of further
Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505
Jordan M. Cloyd, Sarah Colby, Katherine A. Guthrie, Andy M. Lowy, E. Gabrielle Chiorean, Phillip Philip, Davendra Sohal, and Syed Ahmad
/m 2 and 5-fluorouracil, 2,400 mg/m 2 , infused over 46 hours and administered every 2 weeks, for a total of 6 neoadjuvant doses and 6 adjuvant doses) or GA (nab-paclitaxel, 125 mg/m 2 followed by gemcitabine, 1,000 mg/m 2 , administered every week, 3
Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma
+ everolimus (n=12), exemestane + entinostat (n=2), or fulvestrant + palbociclib (n=2). The most common regimens after progression on palbociclib were single-agent capecitabine (n=21), eribulin (n=16), nab-paclitaxel (n=15), and exemestane + everolimus (n=12
Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes
Eva Battaglini, David Goldstein, Peter Grimison, Susan McCullough, Phil Mendoza-Jones, and Susanna B. Park
treatments for these cancers: taxanes (docetaxel: n=322 [32.7%]; paclitaxel: n=312 [31.6%]), platinum-based chemotherapies (oxaliplatin: n=123 [12.5%]; cisplatin: n=53 [5.4%]), thalidomide (n=87; 8.8%), and bortezomib (n=82; 8.3%). One-quarter of respondents
HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations
Robert W. Carlson, Susan J. Moench, M. Elizabeth H. Hammond, Edith A. Perez, Harold J. Burstein, D. Craig Allred, Charles L. Vogel, Lori J. Goldstein, George Somlo, William J. Gradishar, Clifford A. Hudis, Mohammad Jahanzeb, Azadeh Stark, Antonio C. Wolff, Michael F. Press, Eric P. Winer, Soonmyung Paik, Britt-Marie Ljung, and for the NCCN HER2 Testing in Breast Cancer Task Force
cyclophosphamide followed by paclitaxel. 35 These results support the hypothesis that the pro-proliferative/pro-angiogenic/pro-apoptotic/ invasive signals characteristic of dysregulated c-myc genes 42 acting in concert with the anti-apoptotic signals associated
HSR20-108: Treatment Patterns and Outcomes in US Adults with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study of First-Line Treatments
Ashley Tabah, David Huggar, Ronda Copher, Marc Tian, and Ali McBride
analysis included adult patients diagnosed with mNSCLC who initiated nab-paclitaxel, sb-paclitaxel, or PD-L1 based 1L therapy from 1/1/2011 to 12/31/2017. Patients were continuously enrolled (CE) with medical and pharmacy benefits ≥6 months prior to mNSCLC
HSR22-145: Pembrolizumab Plus Chemotherapy for First-Line Treatment of Advanced Triple-Negative Breast Cancer – A Network Meta-Analysis
Amin Haiderali, Min Huang, Wilbur Pan, Grace Fox, Dylan Maciel, and Andrew Frederickson
Background : Pembrolizumab+chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine/carboplatin) was recently granted FDA and EMA approval for first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer
Counterpoint: The Argument for Combination Chemotherapy in the Treatment of Metastatic Breast Cancer
Mary Cianfrocca and William J. Gradishar
cancer: phase III trial results . J Clin Oncol 2002 ; 20 : 2812 – 2823 . 4. O'Shaughnessy J Nag S Calderillo-Ruiz G . Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pretreated metastatic
Oncology Research Program
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced or Recurrent Endometrioid Endometrial
